Primary Office

Address:
Kidz Medical Services, Inc.
3100 SW 62 Avenue -NE Wing #121
Miami, FL-33155
Phone Number: 305-662-8360

Education

Fellowship - MD Anderson Cancer Center
Medical School - Escuela Autonoma de Ciencias Medicas
Residency - Driscoll Children's Foundation's Hospital

Board Certifications

American Board of Pediatrics (Pediatrics) - Certified
American Board of Pediatrics (Ped Hemat-Onc) - Certified


Pediatric Hematology-Oncologist
 
Dr. De Angulo received his medical degree at the Escuela de Ciencias Medicas/Universidad Autonoma de Centro America in San Jose, Costa Rica. He completed his residency in pediatrics at Driscoll Children’s Hospital/Texas A&M University College of Medicine and a fellowship in pediatric hematology-oncology at the University of Texas M. D. Anderson Cancer Center in Houston, Texas. During his fellowship he was awarded the Young Investigator Travel Award by the American Society of Pediatric Hematology Oncology. Dr. De Angulo is board certified in pediatrics and pediatric hematology-oncology. Dr. De Angulo actively participates in research. He has published and has presented research outcomes at numerous national and international conferences.

Current Appointment:
  • Director of Leukemia and Lymphoma Director of Hemophilia Treatment Center Clinical Associate Professor of Pediatrics Herbert Wertheim College of Medicine Florida International University
  • Nicklaus Children's Hospital 03/2014 - present
  • Nicklaus Children’s Hospital
  • Department of Hematology-Oncology and Stem Cell Transplant 07/07- present
 
Post Graduate Training:
  • The University of Texas M.D. Anderson Cancer Center Fellowship in Pediatric Hematology-Oncology - 07/04 - 06/07
  • Driscoll Children’s Hospital/Texas A&M University Residency in Pediatrics - 07/01 - 06/04
 
Medical Education:
Escuela de Ciencias Medicas/ Universidad Autonoma de Centro America San Jose, Costa Rica
Licenciado en Medicina y Cirugia 07/94 -12/99

Licensure:
Florida License #: ME 98389
 
Honors and Awards:
  • Castle Connolly Top Doctors 2017
  • Castle Connolly Top Doctors 2016
  • Castle Connolly Top Doctors 2015
  • Compassionate Doctor Recognition 2014
  • Compassionate Doctor Recognition 2013
  • Compassionate Doctor Recognition 2012
  • Consumers’ Research Council of America Guide to America’s Top Oncologists 2012
  • Consumers’ Research Council of America Guide to America’s Top Oncologists 2011
  • Compassionate Doctor Recognition 2011
  • Consumers’ Research Council of America Guide to America’s Top Oncologists 2010
  • Compassionate Doctor Recognition 2010
  • Consumers’ Research Council of America Guide to America’s Top Oncologists 2009
  • Compassionate Doctor Recognition 2009
  • ASPHO Young Investigator Travel Award 2007
  • Awarded the distinction of commencement speaker for residency graduation 2003
  • Texas A&M/Driscoll Children’s Hospital Resident of the Year 2003
  • Awarded Designated Texas Primary Care Resident 2003
  • Texas A&M/Driscoll Children’s Hospital Resident of the Year 2002
  • Awarded Designated Texas Primary Care Resident 2002
 
Publications:
Articles:
  • Lissitchkov T, Mandan B, Khaya C, Zozulya N, Ross C, Karimi K, De Angulo G, Almomen A, Schwartz B, Solomon C, Knaub S, Peyvandi F. Efficacy and safety of a new human fibrinogen concentrate in patients with congenital fibrinogen deficiency: an interim analysis of a phase III trial. Transfusion (2017) 10.1111/trf.14421.
  • Zapata CP. Cuglievan B, Zapata CM, Olavarrieta R, Raskin S, Desai K, De Angulo G. PET/CT versus bone marrow biopsy in the initial evaluation of bone marrow infiltration in various pediatric malignancies. Pediatric Blood & Cancer 09/2017 DOI: 10.1002/pbc.26814
  • Cuglievan B, DePombo A, De Angulo G. Aplastic anemia: the correct nomenclature matters. Haematologica. (2016) 101, e391; Doi:10.3324/HAEMATOL.2016.146522
  • Li S, Amat D, Peng Z, Vanni S, Raskin S, De Angulo G, Othman MA, Graham R, Leblanc R. Transferrin conjugated nontoxic carbon dots for doxorubicin delivery to target pediatric brain tumor cells. Nanoscale (2016) Doi: 10.1039/C6NR05055G.
  • Graham R, Hernandez F, Puerta N, De Angulo G, Webster K, and Vanni S. Resveratrol augments ER stress and cytotoxicity of glycolytic inhibition in neuroblastoma via downregulation of Akt: mechanism independent of SIRT1. Experimental & Molecular Medicine (2016) 48, e210; Doi:10.1038/enm.2015.116.
  • Alrazzak MA, ZablahAlabi J, Alrazzak B, De Angulo G. A concurrent episode of two neoplasms in a toddler‑age child. Avicenna Journal of Medicine. 4(2): 48-50
  • De Angulo G, Nair S, Lee V, Khatib Z, Ragheb J, Sandberg D. Nonoperative management of solitary eosinophilic granulomas of the calvaria. Journal of Neurosurgery: Pediatrics. Published online May 10, 2013; Doi: 10.3171/2013.4.PEDS12482.
  • De Angulo G, Wei J, Sun W, Hussain SF, Vasquez H, Jordan JT, Weinberg J, Wolff J, Koshkina NV, Heimberger AB. Topotecan enhances immune clearance of gliomas. Cancer Immunology and Immunotherapy. 58(2):259-70. 2009
  • De Angulo G, Yuen C, Palla S, Anderson P, Zweidler-McKay P. Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: implications for risk stratification and future studies. Cancer 112:407-415. 2008
  • Jordan JT, Sun W, Farzana SH, De Angulo G, Weinberg J, Heimberger AH. Preferential Migration of T Regulatory Cells Mediated by Glioma-Secreted Chemokines. Cancer Immunology and Immunotherapy 57(1):133-137.2008
  • De Angulo G, Hernandez M, Morales-Arias J, Herzog C, Anderson P, Wolff J, Kleinerman ES. Early lymphocyte recovery as a prognostic indicator for high-risk Ewing’s sarcoma. Journal of Pediatric Hematology-Oncology 29(1): 48-52. 2007
  • De Angulo G, Sun W, Heimberger AB. Immunochemotherapy in high grade gliomas. Letters in Drug Design and Discovery 3(8): 513-523. 2006
  • Baillargeon J, Langevin A, Mullins J, Ferry R, De Angulo G, Thomas P, Estrada J, Pitney A, Pollock B. Transient hyperglycemia in Hispanic children with acute lymphoblastic leukemia. Pediatric Blood & Cancer 45(7): 960-963, 2005.
 
Book Chapters:
  • De Angulo, G. Cortes, J. Mejia, R. Oncologic Emergencies. Pediatric Fundamental Critical Care Support. June 2017 Vol III. Editor: Mejia. R
  • De Angulo, G. Cortes, J. Mejia, R. Oncologic Emergencies. Pediatric Fundamental Critical Care Support. June 2013 Vol II. Editor: Mejia. R
  • De Angulo, G. Hematology: Coagulation and Transfusions. Pediatric Fundamental Critical Care Support. May 2008. Vol I. Editor: Mejia. R
 
Abstracts:
  • Trabal A, Bardi G, Maher O, Gomara R, Khatib Z, De Angulo G. Sinusoidal obstruction syndrome and susceptibility to bleeding after gastric tube placement. Pediatric Blood and Cancer. 65. 2018
  • Anderson P, Ghisoli M, Barve M, Gill J, Wexler L, De Angulo G, Neville K, Manning L, Wallraven G, Senzer N, Birkhofer M, Nemunaitis J. A VigilTM (bi-shRNAfurin and GMCSF Engineered Autologous Tumor Cell Immunotherapy) Versus Gemcitabine + Docetaxel for Ewing's Sarcoma and with Cryoablation in Ewing Family Tumors. Journal of Clinical Oncology 2017.
  • De Cordoba N, Vallejo F, Gonzalez W, Ioni DO, De Angulo G, Vanni S, Graham R. Targeting the metabolic pathway of neuroblastoma. Pediatric Blood and Cancer. 64 :():S47, 2017.
  • Febres MC, Samuels S, Graham R, De Angulo G, Vanni S. Anti-Cancer effects of atypical antipsychotic drugs on brain tumor cell lines. Pediatric Blood and Cancer. 64: S53, 2017.
  • Zapata C, Myrthil N, Cortesi-Gesten A, Cosme-Blanco W, Cuglievan B, Rodriguez G, De Angulo G, Vanni S, Graham R. Withaferin A as a novel differentiating agent for treatment of neuroblastoma. Pediatric Blood & Cancer. 62:S101, 2015.
  • Zapata CP. Cuglievan B, Zapata CM, Olavarrieta R, Raskin S, Desai K, De Angulo G. PET/CT versus bone marrow biopsy in the initial evaluation of bone marrow infiltration in various solid tumors. Pediatric Blood & Cancer. 62():S106, 2015
  • Cuglievan B, Hernandez F, De Angulo G, Graham R. Role for Sirtuins in chemoresistance in neuroblastoma Pediatric Blood & Cancer. 61():S34, 2014
  • Morrison A, Badia P, De Angulo G. Ensuring optimal therapy: maintaining anthracycline treatment after decline in ejection fraction with sepsis. Pediatric Blood & Cancer. 61():S52, 2014
  • Ale H, Castella-Sanchez A, Poppiti RJ, Brathwaite C, De Angulo G. An Association of CD68+ tumor infiltrating macrophages and EBV status with outcome in pediatric Hodgkin lymphoma. Archive of Pathology & Laboratory Medicine. 10.2013.
  • Shaw A, De Angulo G. Use of Pamidronate for the treatment of steroid induced avascular necrosis in pediatric leukemia patients. Pediatric Blood & Cancer. 60:S49-50, 2013.
  • Cuglievan B, Galvez J, De Angulo G. Epstein Barr infection obscuring pediatric chronic eosinophilic leukemia associated t(1, 5) with excellent response to targeted therapy. Pediatric Blood & Cancer. 60:S58.2013.
  • Alrazzak M, Zablah J, De Angulo G. Orbital rhabdomyosarcoma and adrenocortical tumor simultaneously in a 21 month old child in the context of Li Fraumani Syndrome. Pediatric Blood & Cancer. 60:S80. 2013
  • Hernandez F, Puerta N, Vanni S, De Angulo G, Graham R,. Combined AKT and glycolysis inhibition for the treatment of neuroblastoma. Pediatric Blood and Cancer 58(7): 695. 2012.
  • De Angulo G, Nair S, Khatib Z, Lee V, Ragheb J, Zoeller G, Sandberg D. Observation as a strategy for management of solitary calvarial eosinophilic granuloma. Pediatric Blood and Cancer 56(6): 925. 2011.
  • De Angulo G, Muthusami S, Fort J, Pefkarou A, Escalon E, Khatib Z. Coexpression of inversion 16 and Philadelphia chromosome in a patient with de novo acute myelogenous leukemia. Pediatric Blood and Cancer 56(6): 933. 2011.
  • Khatib Z, Naqvi A, De Angulo G, Diaz A. Novel approaches to treatment of embryonal tumor with abundant neuropil and true rosettes. Pediatric Blood and Cancer 56(6): 964. 2011.
  • Anderson P, Subbiah V, Salvador L, Salazar-Abshire M, Sutphin R, De Angulo G, Garroutte P, Walker W. Cost-effective outpatient chemotherapy for bone Sarcomas: importance of ALC and using excellent anti-emetics to avoid pennywise and pound foolish decisions. Pediatric Blood and Cancer 55(5):877 Abstract PD- 011.
  • De Angulo G, Yuen C, Palla S, Anderson P, Zweidler-McKay P. Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: implications for risk stratification and future studies. Pediatric Blood and Cancer 48(6): 605. 2007. Abstract 5725.3
  • Jordan JT, Sun W, Hussain SF, De Angulo G, Weinberg J, Heimberger AB. Preferential Migration of T Regulatory Cells Mediated by Glioma-Secreted Chemokines. The Journal of Immunology 178: Abstract 49.3.
  • Levy A, Sabella-River R, Ghisoli M, De Angulo G, Palla S, Anderson P, ZweidlerMckay. Absolute Lymphocyte Count Predicts Outcome in Pediatric Patients with Non-Hodgkin’s Lymphoma. Pediatric Blood and Cancer 48(6): 618. 2007. Abstract 5869.10
  • De Angulo G, Yuen C, Palla S, Anderson P, Zweidler-McKay P. Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: implications for risk stratification and future studies. Blood 108(11): 644a-45a. 2006. Abstract 2276.
  • De Angulo G, Vasquez H, Koshkina NV, Sun W, Hussain SF, Kleinerman ES, Wolff J, Sawaya R, Heimberger AB. Topotecan Induces FAS on Gliomas and Enhances Immunological Clearance. Neuro-Oncology 8(4): 426. 2006. Abstract IM 04.
  • De Angulo G, Morales-Arias J, Herzog C, Anderson P, Wolff J, Kleinerman ES. Early lymphocyte recovery as a prognostic indicator for high-risk Ewing’s sarcoma. Pediatric Blood and Cancer 47(4): 434, 2006. Abstract PD.026
  • De Angulo G, Morales-Arias J, Herzog C, Anderson P, Wolff J, Kleinerman ES. Early lymphocyte recovery as a prognostic indicator for high-risk Ewing’s sarcoma. Pediatric Blood and Cancer 46(6): 674-675, 2006. Abstract 2844.115
 
Research Experience:
Primary Investigators: G. De Angulo (PI)
Clinical: Phase II investigating the clinical benefit if FANG vaccine for recurrent Ewing's sarcoma.
07/15 – present
 
Primary Investigators: G. De Angulo (PI)
Clinical: B4541006 - An open-label study to evaluate the safety and pharmacokinetics of PF-06412528 in children 7-17 years for the treatment of moderate-to-severe chronic pain.
06/15 – present
 
Primary Investigators: G. De Angulo (PI)
Clinical: Forma 02 - Prospective, open-label, uncontrolled, phase III study to assess the efficacy and safety of Octafibrin for on-demand treatment of acute bleeding and to prevent bleeding during and after surgery in subjects with congenital fibrinogen deficiency.
05/15 – 12/2016
 
Primary Investigators: G. De Angulo (PI)
Clinical: Will 20 Surveillance of Safety and Efficacy of wilate® in patients with von Willebrand disease.
09/14 – 12/16

Primary Investigators: G. De Angulo (PI)
Clinical: GENA05 - Immunogenicity, Efficacy and Safety of Treatment with Human- cl rhFVIII in previously untreated patients with severe Haemophilia A.
09/14 – present
 
Primary Investigators: G. De Angulo (PI)
Clinical: B1931022 - An open-label randomized Phase III study of Inotuzumab
Ozogamicin compared to a defined Investigator’s Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL).
04/13 – 06/15
 
Primary Investigators: D. Sandberg and G. De Angulo (sub-PI)
Clinical: Phase I/II investigating the clinical benefit of an intraventricular methotrexate to the fourth ventricle for patients with de novo or recurrent medulloblastoma and atypical teratoid rhabdoid tumors located in the fourth ventricle.
06/11 – 05/12
 
Primary Investigators: G. De Angulo and E. Escalon
Clinical: Investigating the clinical benefit of an antibody against Insulin Growth Factor 1 Receptors for patients with refractory neuroblastoma and sarcomas.
 
Primary Investigators: G. De Angulo and P. Zweidler-McKay
Clinical: A prospective study examining the subset populations of lymphocytes on day 15, 21, and 28 of induction chemotherapy for ALL and AML.
4/06- 5/2013
 
Primary Investigators: G. De Angulo and A. Heimberger
Basic Science: Investigated if there was a synergistic effect with topotecan and immunotherapy (PEP-3 vaccine) for glioblastoma multiforme. This research was funded by the Department of Pediatrics at M. D. Anderson Cancer Center and Dr. Amy Heimberger of the Department of Neurosurgery.
10/05 – 6/07
 
Primary Investigators: A. Heimberger
Basic Science: Analyzed if the presence of certain cytokines in patients causes a preferential migration of regulatory T cells in patients with glioblastoma multiforme. This research was funded by the Department of Pediatrics at M. D. Anderson Cancer Center and Dr. Amy Heimberger of the Department of Neurosurgery.
7/06 – 3/07
 
Primary Investigators: G. De Angulo and P. Zweidler-McKay
Clinical: A retrospective study analyzing data from 180 consecutive patients with non-hodgkin’s lymphoma. Investigating if lymphocyte counts predict survival.
12/06- 2/07
 
Primary Investigators: G. De Angulo and A. Heimberger
Clinical: A retrospective and prospective study analyzing if the presence of EGFRvIII on medulloblastoma is associated with poor prognosis. The primary benefit of this study is that patients may then benefit from the PEP-3 vaccine.
4/06- 6/06
 
Primary investigators: G. De Angulo and P. Zweidler-McKay
Clinical: A retrospective study analyzing data from 171 consecutive patients treated at the M. D. Anderson Cancer Center for AML and ALL. We examined lymphocyte recovery and its correlation with relapse free survival and time to progression.
1/06- 10/06
 
Primary Investigators: G. De Angulo and C. Herzog
Clinical: A retrospective study analyzing data from 27 consecutive patients treated at the M. D. Anderson Cancer Center. We evaluated the absolute lymphocyte count in high-risk Ewing’s sarcoma and its association with relapse and overall survival.
7/05- 3/06
 
Primary Investigator: J. Baillargeon
Clinical: A retrospective study analyzing from 63 consecutive patients treated at Santa Rosa and Driscoll Children’s Hospital for ALL. We analyzed the incidence of transient hyperglycemia in Hispanic children being treated for acute lymphoblastic leukemia.
2/04- 5/06
 
Teaching Experience:
Florida International University School of Medicine
Responsible for lectures to medical students and clinical educator at Miami Children’s Hospital
7/10- present
 
Miami Children's Hospital
Responsible for daily lectures to medical students and residents.
7/07-present
 
The University of Texas M. D. Anderson Cancer Center
Fellows are responsible for monthly lectures of pediatric oncology given to third year medical students and residents of University of Texas at Houston School of Medicine.
7/04- 6/07; Houston, TX
 
Driscoll Children’s Hospital
The senior resident is responsible to preside over teaching rounds and give daily lectures for junior residents and students from Texas A&M College of Health and Sciences and Texas College of Osteopathic Medicine.
7/03- 6/04; Corpus Christi, TX
 
St. John Vianney College Seminary
Taught general biology to university sophomores.
8/00-12/00; Miami, FL

Board Certifications:
  • Recertification American Board of Pediatrics 2016
  • Recertification in Pediatric Hematology-Oncology 2016
  • American Board of Pediatrics - MOC 2011
  • Pediatric Hematology-Oncology 2009
  • American Board of Pediatrics 2004
 
Memberships and Committees:
  • Scientific Advisory Board of Biomark Pharmaceuticals – 2017
  • Editorial Board – ANNALS OF HEMATOLOGY & ONCOLOGY 2014 -Present
  • Scientific Advisory Committee 2012 - 2015
  • Morbidity Mortality Committee 2012 (CHAIR) – 2014
  • Medical Executive Committee Miami Children’s Hospital 2012 - 2014
  • Mystic Force Foundation Board Member 2011 - Present
  • Clinical Ethics Committee at the M. D. Anderson Cancer Center 2007
  • American Society of Hematology 2005
  • American Society of Pediatric Hematology-Oncology 2005 Resident
  • Representative of the Resident Advisory Committee 2004

Languages:
Fluent in writing and speaking Spanish
 
Other Awards and Accomplishments:
  • Medical School Representative
  • All-American High School Swimmer Candidate
  • First Team All-County Swimmer 1988-1990

Publications

Zapata, C.P., Cuglievan, B., Zapata, C.M., Olavarrieta, R., Raskin, S., Desai, K., De Angulo, G. (2018). PET/CT versus bone marrow biopsy in the initial evaluation of bone marrow infiltration in various pediatric malignancies. Pediatric Blood & Cancer, 65(2), . View in Pubmed

Lissitchkov, T., Madan, B., Djambas Khayat, C., Zozulya, N., Ross, C., Karimi, M., ..., De Angulo, G., et al (2018). Efficacy and safety of a new human fibrinogen concentrate in patients with congenital fibrinogen deficiency: an interim analysis of a Phase III trial. Transfusion, 58(2), 413-422. View in Pubmed

Graham, R.M., Hernandez, F., Puerta, N., De Angulo, G., Webster, K.A., Vanni, S. (2016). Resveratrol augments ER stress and the cytotoxic effects of glycolytic inhibition in neuroblastoma by downregulating Akt in a mechanism independent of SIRT1. Experimental & Molecular Medicine, 48(), e210. View in Pubmed

Cuglievan, B., DePombo, A., De Angulo, G. (2016). Aplastic anemia: the correct nomenclature matters. Haematologica, 101(9), e391. View in Pubmed

Li, S., Amat, D., Peng, Z., Vanni, S., Raskin, S., De Angulo, G., et al (2016). Transferrin conjugated nontoxic carbon dots for doxorubicin delivery to target pediatric brain tumor cells. Nanoscale, 8(37), 16662-16669. View in Pubmed

De Angulo, G., Cortes, J., Mejia, R. (2014). “Oncologic emergencies” . Society of Critical Care Medicine. Pediatric Fundamental Critical Care Support. Vol. II. .

Alrazzak, M.A., ZablahAlabi, J., Alrazzak, B., De Angulo, G. (2014). A concurrent episode of two neoplasms in a toddler age child. Avicenna Journal of Medicine, 4(2), 48-50. View in Pubmed

De Angulo, G., Nair, S., Lee, V., Khatib, Z., Ragheb, J., Sandberg, D. (2013). Nonoperative management of solitary eosinophilic granulomas of the calvaria. Journal of Neurosurgery. Pediatrics, 12(1), 1-5. View in Pubmed

Hernandez, F., Puerta, N., Vanni, S., DeAngulo, G., Graham, R. (2012). Combined AKT and glycolysis inhibition for the treatment of neuroblastome. Pediatric Blood & Cancer, 58(7), 695.

DeAngulo, G., Muthusami, S., Fort, J., Pefkarou, A., Escalon, E., Khatib, Z. (2011). Co-expression of inversion 16 and Philadelphia chromosome in a patient with de novo acite myelogenous leukemia. Pediatric Blood & Cancer, 56(6), 933.

Khatib, Z., Naqvi, A., DeAngulo, G., Diaz, A. (2011). Novel approaches to treatment of embryonal tumor with abundant neuropil and true rosettes. Pediatric Blood & Cancer, 56(6), 964.

DeAngulo, G., Nair, S., Khatib, Z., Lee, V., Ragheb, J., Zoeller, G., et al (2011). Observation as a strategy for management of solitary calvarial eosinophilic granuloma. Pediatric Blood & Cancer, 56(6), 925.

De Angulo, G., Wei, J., Sun, W., Hussain, S.F., Vasquez, H., Jordan, J.T., Weinberg, J., Wolff, J., Koshkina, N.V., Heimberger, A.B. (2009). Topotecan enhances immune clearance of gliomas. Cancer Immunology and Immunotherapy, 58(2), 259-270. View in Pubmed

De Angulo, G., Yuen, C., Palla, S.L., Anderson, P.M., Zweidler-McKay, P.A. (2008). Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: implications for risk stratification and future studies. Cancer, 112(2), 407-415. View in Pubmed

De Angulo, G. (2008). “Hematology: coagulation and transfusions” . Society of Critical Care Medicine. Pediatric Fundamental Critical Care Support. Vol. I.

Jordan, J.T., Sun, W., Farzana, S.H., De Angulo, G., Weinberg, J., Heimberger, A.H. (2008). Preferential migration of T regulatory cells mediated by glioma-secreted chemokines. Cancer Immunology and Immunotherapy, 57(1), 133-137. View in Pubmed


A physician identified with a Pediatric Specialists of America (PSA) logo is an employee of PSA, which is part of Nicklaus Children's Health System. All other physicians listed on the website are in private medical practices.